Didanosine associated with non-cirrhotic portal HTN

Physicians who care for HIV patients should be aware of a safety warning of the association between the HIV drug didanosine and non-cirrhotic portal HTN with esophageal varices. There have been 42 reported cases and 4 deaths (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment